DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biopharmaceutical company, has a key clinical trial catalyst to watch this month involving its novel treatment for preeclampsia.
Preeclampsia is a serious and potentially life-threatening pregnancy complication that typically emerges after 20 weeks of gestation. It is characterised by high blood pressure and kidney dysfunction (often indicated by protein in the urine), and can lead to serious outcomes for both mother and baby. Currently, there are no FDA-approved therapies for preeclampsia, and the only 'cure' is to deliver the baby, often prematurely. In the U.S., as many as 50,000 severe cases are reported each year.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.